Despite recent advances in chronic heart failure management (either pharmacological or
non-pharmacological), the prognosis of heart failure (HF) patients remains poor. This poor …

Background Heart failure (HF) may complicate acute coronary syndrome (ACS) and is
associated with a high burden of short-and long-term morbidity and mortality. Only limited …

Therapeutic approaches to the management of heart failure have traditionally focused on
short-term hemodynamic and symptomatic goals, but present evidence suggests that most …

Heart failure continues to significantly impact morbidity and mortality after acute myocardial
infarction (AMI), especially when associated with left ventricular systolic dysfunction (LVSD) …

Background Guideline recommendations for the treatment of heart failure with mildly
reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of …

Heart failure (HF) can rightfully be called the epidemic of the 21st century. Historically, the
only available medical treatment options for HF have been diuretics and digoxin, but the …

Short-term goals of heart failure management are directed toward relieving symptoms such
as shortness of breath, decreased exercise tolerance, and lower-extremity edema and …

Pharmacological treatment of heart failure with preserved ejection fraction: A glimpse of light at
the end of the tunnel? : Research Bank Skip to content Australian Catholic University Home …

Many conditions culminate in heart failure (HF), a multi‐organ systemic syndrome with an
intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal …

Heart failure (HF) is a progressively deteriorating medical condition that significantly reduces
both the patients' life expectancy and quality of life. Even though real progress was made in …